Zeiss Medical Technology has obtained CE mark approval for CIRRUS PathFinder, its new artificial intelligence (AI)-powered tool designed to enhance clinical workflows with automated optical coherence tomography (OCT) assessments.
CIRRUS PathFinder leverages advanced deep learning algorithms to identify abnormal macular OCT B-scans.
The tool also enhances OCT A image quality and diagnostic capabilities to boost efficiency and patient care through improved image quality and segmentation.
Its fully integrated AI-powered decision support algorithm allows for real-time assessment of numerous scans without needing third-party platforms.
During image acquisition, the integrated AI identifies areas needing further imaging, optimising clinicians’ focus on essential tasks.
Zeiss Medical Technology ophthalmology strategic business unit head Magnus Reibenspiess said: “At Zeiss, we continue to develop digital diagnostic tools that help streamline workflows, lower costs, improve outcomes, and elevate the patient experience.
“The AI decision support capabilities of Zeiss CIRRUS PathFinder help enable faster, more informed and actionable diagnostics for a better clinical and patient experience.”
The CIRRUS PathFinder offers high-speed image capture with HD detail and integrated AI decision support.
It supports easy integration with existing patient data and enables clinicians to make more informed decisions swiftly and accurately.
The updated software features an expanded Reference Database (RDB), which is three times larger than the previous version, and enhanced cybersecurity.
The updated CIRRUS software updates are available in select markets.
Zeiss Medical Technology digital business unit head Euan Thomson said: “ZEISS is harnessing the power of data and artificial intelligence to deliver integrated digital solutions that are paving the way for the next era in ophthalmic care.
“Our strategic focus on digitally connected workflows has placed us at the forefront for enabling ophthalmologists with powerful AI-driven capabilities, like those that have been fully integrated into Zeiss CIRRUS PathFinder.”
Zeiss Medical Technology chronic disease management head Anuj Kalra said: “With PathFinder AI Decision Support, our game-changing technology identifies OCT B-scans that may require additional review, raising our advanced diagnostic portfolio to a new level of patient care support.”
Earlier this year, Zeiss received China’s National Medical Products Administration (NMPA) approval for its retinal imaging device, CLARUS 700.
